



FORM HDP-1449 (Based on Form PTO-1449)

**PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITATION**
(Use several sheets if necessary)

Sheet 1 of 4

ATTORNEY DOCKET NO.	SERIAL NO.
3124/9A/US (Pfizer Ref. 31134A/USA)	10/730,403
APPLICANT	
Thomas E. Barta et al.	
FILING DATE	GROUP
December 8, 2003	1625

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	(If appropriate) Filing Date
1.	CV	4,595,700	6/17/1986	Donald et al.	514/616	
2.		5,932,595	8/3/1999	Bender et al.	514/317	
3.		6,013,649	1/11/2000	Freskos et al.	514/237.8	
4.		6,300,514	10/9/2001	Takahashi et al.	560/17	
5. (Office action and notices of allowance enclosed)		6,541,489, including 12/17/01 Office action, 5/16/02 notice of allowance, and 11/08/02 notice of allowance	4/1/2003	Barta et al.	514/330	7/31/2000
6. (Office action and notice of allowance enclosed)		6,689,794, including 4/11/03 Office action and 5/28/03 notice of allowance	2/10/2004	Barta et al.	514/318	05/10/2002
7. (Office action and notice of allowance enclosed)		6,750,233, including 11/18/02 Office action and 5/09/03 notice of allowance	6/15/2004	Barta et al.	514/336	09/17/2001
8. (pending claims enclosed)		Publ. No. 2004-0024024 (Appl. No. 10/291,983), including pending claims		Freskos et al.	514/326	11/12/2002
9. (notice of allowance and allowed claims enclosed)		Publ. No. 2004-0048852 (Appl. No. 10/337,942), including allowed claims and 2/13/04 notice of allowance		Barta et al.	514/317	01/07/2003
10. (notice of allowance and allowed claims enclosed)		Publ. No. 2004-0110805 (Appl. No. 10/657,034), including allowed claims and 7/21/04 notice of allowance		Freskos et al.	514/256	09/05/2003
11. (pending claims enclosed)		Publ. No. 2004-0235818 (Appl. No. 10/747,796), including pending claims		Barta et al.	514/315	12/29/2003

Examiner: <i>Oh</i>	Date Considered: 2/23/06
---------------------	--------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

EV 327050948 US

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> <p>Sheet 2 of 4</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	3124/9A/US (Pfizer Ref. 31134A/USA)	10/730,403
	APPLICANT	
	Thomas E. Barta et al.	
	FILING DATE	GROUP
	December 8, 2003	1625

U.S. PATENT DOCUMENTS						
Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/Subclass	(If appropriate) Filing Date
12. (enclosed)	<i>ll</i>	Pending claims from Appl. No. 10/992,483		Freskos et al.	TBA	11/07/2004

FOREIGN PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/Subclass	Translation Yes No	
13.	<i>ll</i>	EP 0 266 182	5/4/1988	Europe	C07D 307/32		
14.		EP 0 606 046	7/13/1994	Europe	C07D 213/42		
15.		EP 0 780 386	6/25/1997	Europe	C07D 309/08		
16.		EP 0 930 067	7/21/1999	Europe	A61K 31/40		
17.		EP 1 081 137	3/7/2001	Europe	C07D 211/96		
18. (partial translation enclosed)		JP 4-338331	11/25/1992	Japan	A61K 31/365	partial	
19.		WO 90/05719	5/31/1990	PCT	C07C 323/62		
20.		WO 93/20047	10/14/1993	PCT	C07C 317/44		
21.		WO 94/02466	2/3/1994	PCT	C07D 221/14		
22.		WO 94/24140	10/27/1994	PCT	C07H 13/04		
23.		WO 95/09841	4/13/1995	PCT	C07C 323/60		
24.		WO 95/13289	5/18/1995	PCT	C07K 5/062		
25.	<i>ll</i>	WO 95/29892	11/09/1995	PCT	C07D 207/327		

Examiner: <i>chy</i>	Date Considered: <i>2/23/06</i>
----------------------	---------------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> <p>Sheet 3 of 4</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	3124/9A/US (Pfizer Ref. 31134A/USA)	10/730,403
	APPLICANT	
	Thomas E. Barta et al.	
	FILING DATE	GROUP
	December 8, 2003	1625



FOREIGN PATENT DOCUMENTS							
Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No	
26.	cl	WO 96/06074	2/29/1996	PCT	C07C 259/06		
27.		WO 96/11209	4/18/1996	PCT	C07K 5/06		
28.		WO 97/20824	6/12/1997	PCT	C07D 241/04		
29.		WO 97/24117	7/10/1997	PCT	A61K 31/19		
30.		WO 98/37877	9/3/1998	PCT	A61K 31/16		
31.		WO 98/38163	9/3/1998	PCT	C07C 323/60		
32.		WO 99/09000	2/25/1999	PCT	C07C 235/00		
33.		WO 99/25687	5/27/1999	PCT	C07D 211/66		
34.		WO 99/42436	8/26/1999	PCT	C07C 239/14		
35.		WO 00/46221	8/10/2000	PCT	C07D 405/12		
36.		WO 00/50396	8/31/2000	PCT	C07D 211/66		
37.		WO 00/59874	10/12/2000	PCT	C07C 259/06		
38.	cl	WO 00/69821	11/23/2000	PCT	C07D 211/66		


OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
39.	cl	Brown, P.D., "Synthetic Inhibitors of Matrix Metalloproteinases," in <i>Matrix Metalloproteinases</i> , pp. 243-61 (Edited by Parks, W.C. & Mecham, R.P., Academic Press, San Diego, CA 1998).
40.	cl	Dack, et al., <i>Preparation of N-hydroxytetrahydropyridylsulfonacetamides and related compounds as matrix metalloprotease inhibitors</i> , CA 131:44740 (1999) [CA Plus Accession No. 1999:388166]

Examiner: <i>cl</i>	Date Considered: 2/23/06
---------------------	--------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<p>FORM HDP-1449 (Based on Form PTO-1449)</p> <p>PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)</p> <p>Sheet 4 of 4</p>	ATTORNEY DOCKET NO.	SERIAL NO.
	3124/9A/US (Pfizer-Ref. 31134A/USA)	10/730,403
	APPLICANT	
	Thomas E. Barta et al.	
	FILING DATE	GROUP
	December 8, 2003	1625

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
41.		Denis et al., <i>Matrix metalloproteinase inhibitors: Present achievements and future prospects</i> , INVEST. NEW DRUGS, 15:175-185 (1997).
42.		Gearing et al., <i>Processing of tumour necrosis factor-α precursor by metalloproteinases</i> , NATURE, 370:555-557 (1994).
43.		Kenyon et al., <i>A model of angiogenesis in the mouse cornea</i> , INVEST. OPHTHALMOL. VIS. SCI., 37(8):1625-1632 (1996).
44.		Knight et al., <i>A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases</i> , FEBS LETT., 296(3):263-266 (1992).
45.		Luckow et al., <i>Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in escherihia coli</i> , J. VIROL., 67:4566-4579 (1993).
46.		McClure, et al., <i>Matrix metalloprotease (MMP)-13 selective inhibitors for treatment of arthritis deformans and other MMP-related diseases</i> , CA 131:125454 (1999) [CA Plus Accession No. 1999:468334]
47.		McGeehan et al., <i>Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor</i> , NATURE, 370:558-561 (1994).
48.		Mitchell et al., <i>Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage</i> , J. CLIN. INVEST. 97(3):761-768 (1996).
49.		Rasmussen et al., <i>Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat</i> , PHARMACOL. THER., 75(1):69-75 (1997).
50.		Reboul et al., <i>The new collagenase, collagnease-3, is expressed and synthesized by human chondrocytes but not by synoviocytes</i> , J. CLIN. INVEST., 97(9):2011-2019 (1996).
51.		Schwartz et al., <i>Synthetic inhibitors of bacterial and mammalian interstitial collagenases</i> , PROG. IN MED. CHEM., 29:271-334 (1992).
52.		Tang, B. L., <i>ADAMTS: A Novel Family of Extracellular Matrix Proteases</i> , INT. J. BIOCHEM. CELL BIO., 33(11):33-44 (2001).
53.		Woessner, J.F., "The Matrix Metalloprotease Family" in <i>Matrix Metalloproteinases</i> , pp.1-14 (Edited by Parks, W.C. & Mecham, R.P., Academic Press, San Diego, CA 1998).

Examiner: 	Date Considered: 2/23/06
---	--------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.